High expression of Ras-specific guanine nucleotide-releasing factor 2 (RasGRF2) in lung adenocarcinoma is associated with tumor invasion and poor prognosis.

Abstract

The expression of Ras-specific guanine nucleotide-releasing factor 2 (RasGRF2) in lung adenocarcinomas was examined using immunohistochemistry in relation to clinicopathological characteristics and prognosis. In comparison to low expression, high expression of RasGRF2 was more closely associated with poor prognosis. Interestingly, expression of phosphorylated epithelial cell transforming 2 (pECT2), which - like RasGRF2 - is also a guanine-nucleotide exchange factor, was also associated with prognosis, and patients with high expression of both RasGRF2 and pECT2 had a much poorer outcome than those who were negative for both.

• Authors: Tomoki Nakagawa, YunJung Kim, Junko Kano, Yoshihiko Murata, Zeinab Kosibaty, Masayuki Noguchi, Noriaki Sakamoto
• Journal: Pathology international (Pathol Int) Vol. 71 Issue 4 Pg. 255-260 (Apr 2021) ISSN: 1440-1827 [Electronic] Australia
• PMID: 33709437 (Publication Type: Journal Article)
• Copyright: © 2021 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Chemical References

• Biomarkers, Tumor
• Guanine Nucleotide-Releasing Factor 2
• RASGRF2 protein, human
• ras Guanine Nucleotide Exchange Factors

Topics

• Adenocarcinoma of Lung (pathology)
• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (metabolism)
• Female
• Guanine Nucleotide-Releasing Factor 2 (metabolism)
• Humans
• Immunohistochemistry
• Lung Neoplasms (pathology)
• Male
• Middle Aged
• Prognosis
• ras Guanine Nucleotide Exchange Factors (metabolism)